Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their
growth. This phase I trial is studying the side effects and best dose of bortezomib in
treating patients with advanced cancer and liver dysfunction.